- Home
- GNLX vs VIGL Comparison
GNLX vs VIGL Comparison
Compare GNLX & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- VIGL
- Stock Information
- Founded
- GNLX 2001
- VIGL 2020
- Country
- GNLX United States
- VIGL United States
- Employees
- GNLX N/A
- VIGL N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- VIGL Health Care
- Exchange
- GNLX Nasdaq
- VIGL Nasdaq
- Market Cap
- GNLX 112.5M
- VIGL 134.9M
- IPO Year
- GNLX 2023
- VIGL 2022
- Fundamental
- Price
- GNLX $3.44
- VIGL $8.05
- Analyst Decision
- GNLX Strong Buy
- VIGL Buy
- Analyst Count
- GNLX 4
- VIGL 7
- Target Price
- GNLX $17.75
- VIGL $8.00
- AVG Volume (30 Days)
- GNLX 152.2K
- VIGL 1.1M
- Earning Date
- GNLX 08-13-2025
- VIGL 08-12-2025
- Dividend Yield
- GNLX N/A
- VIGL N/A
- EPS Growth
- GNLX N/A
- VIGL N/A
- EPS
- GNLX N/A
- VIGL N/A
- Revenue
- GNLX N/A
- VIGL N/A
- Revenue This Year
- GNLX N/A
- VIGL N/A
- Revenue Next Year
- GNLX N/A
- VIGL N/A
- P/E Ratio
- GNLX N/A
- VIGL N/A
- Revenue Growth
- GNLX N/A
- VIGL N/A
- 52 Week Low
- GNLX $1.60
- VIGL $1.31
- 52 Week High
- GNLX $5.89
- VIGL $8.06
- Technical
- Relative Strength Index (RSI)
- GNLX 65.71
- VIGL 88.18
- Support Level
- GNLX $2.80
- VIGL $7.86
- Resistance Level
- GNLX $3.61
- VIGL $8.05
- Average True Range (ATR)
- GNLX 0.22
- VIGL 0.02
- MACD
- GNLX 0.05
- VIGL -0.15
- Stochastic Oscillator
- GNLX 80.23
- VIGL 73.15
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.